# Xeltis Hemodialysis Access Graft (aXess) US Study

Study · id `cardio:ct-nct06494631` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06494631](<https://clinicaltrials.gov/study/NCT06494631>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06494631

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 140 participants.

## Technical summary

Registry record NCT06494631. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-11 (actual); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 140 participants (planned count; ClinicalTrials.gov record NCT06494631, source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)
- Started: 2024-11-11 (actual) (ClinicalTrials.gov record NCT06494631, source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT06494631, source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)
- Completion: 2032-01 (anticipated) (ClinicalTrials.gov record NCT06494631, source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06494631, source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06494631-2026-07-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Xeltis Hemodialysis Access Graft (aXess) US Study
- Condition: End Stage Renal Disease
- Intervention (Device): Xeltis Hemodialysis Access (aXess) graft
- Lead sponsor: Xeltis
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Xeltis (`cardio:org-xeltis`)

## Provenance

Content hash: f9da6d92b1566727135c001a04c5e930526a3c852f7ce9283b5364d448f37ecc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
